PI3Kα/δ inhibition promotes anti-tumor immunity through direct enhancement of effector CD8+ T-cell activity
Authors:
- Larissa S. CarnevalliLCLarissa S. Carnevalli
- Charles SinclairCSCharles Sinclair
- Molly A. TaylorMTMolly A. Taylor
- Pablo Morentin GutierrezPGPablo Morentin Gutierrez
- Sophie LangdonSLSophie Langdon
- Anna M. L. Coenen-StassACAnna M. L. Coenen-Stass
- Lorraine MooneyLMLorraine Mooney
- Adina HughesAHAdina Hughes
- Laura JarvisLJLaura Jarvis
- Anna StaniszewskaASAnna Staniszewska
- Claire CrafterCCClaire Crafter
- Ben SiddersBSBen Sidders
Open Access
- 27 December 2018
- journal article
- research article
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 6 (1) , 158
Abstract
PI3K inhibitors with differential selectivity to distinct PI3K isoforms have been tested extensively in clinical trials, largely to target tumor epithelial cells. PI3K signaling also regulates the immune system and inhibition of PI3Kδ modulate the tumor immune microenvironment of pre-clinical mouse tumor models by relieving T-regs-mediated immunosuppression. PI3K inhibitors as a class and PI3Kδ specifically are associated with immune-related side effects. However, the impact of mixed PI3K inhibitors in tumor immunology is under-explored. Here we examine the differential effects of AZD8835, a dual PI3Kα/δ inhibitor, specifically on the tumor immune microenvironment using syngeneic models. Continuous suppression of PI3Kα/δ was not required for anti-tumor activity, as tumor growth inhibition was potentiated by an intermittent dosing/schedule in vivo. Moreover, PI3Kα/δ inhibition delivered strong single agent anti-tumor activity, which was associated with dynamic suppression of T-regs, improved CD8+ T-cell activation and memory in mouse syngeneic tumor models. Strikingly, AZD8835 promoted robust CD8+ T-cell activation dissociated from its effect on T-regs. This was associated with enhancing effector cell viability/function. Together these data reveal novel mechanisms by which PI3Kα/δ inhibitors interact with the immune system and validate the clinical compound AZD8835 as a novel immunoncology drug, independent of effects on tumor cells. These data support further clinical investigation of PI3K pathway inhibitors as immuno-oncology agents.Keywords
This publication has 38 references indexed in Scilit:
- Inhibiting PI3Kβ with AZD8186 Regulates Key Metabolic Pathways in PTEN-Null TumorsClinical Cancer Research, 2017
- Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint BlockadeCell, 2017
- Inference of immune cell composition on the expression profiles of mouse tissueScientific Reports, 2017
- PI3K inhibitors in inflammation, autoimmunity and cancerCurrent Opinion in Pharmacology, 2015
- Selective Inhibition of Regulatory T Cells by Targeting the PI3K–Akt PathwayCancer Immunology Research, 2014
- Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cellsProceedings of the National Academy of Sciences, 2014
- The application of transcriptional blood signatures to enhance our understanding of the host response to infection: the example of tuberculosisPhilosophical Transactions of the Royal Society B: Biological Sciences, 2014
- The Long-Term Survival Potential of Mature T Lymphocytes Is Programmed During Development in the ThymusScience Signaling, 2011
- Interleukin-7 mediates the homeostasis of naïve and memory CD8 T cells in vivoNature Immunology, 2000
- Analysing cell division in vivo and in vitro using flow cytometric measurement of CFSE dye dilutionJournal of Immunological Methods, 2000